Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 336

1.

Cough and Eosinophilia.

Diver S, Russell RJ, Brightling CE.

J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1740-1747. doi: 10.1016/j.jaip.2019.04.048.

PMID:
31279462
2.

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab.

George L, Wright A, Mistry V, Sutcliffe A, Chachi L, Haldar K, Ramsheh MY, Richardson M, van der Merwe R, Martin U, Newbold P, Brightling CE.

Int J Chron Obstruct Pulmon Dis. 2019 Jun 5;14:1177-1185. doi: 10.2147/COPD.S198302. eCollection 2019.

3.

Benralizumab for the Prevention of COPD Exacerbations.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA and TERRANOVA Study Investigators.

N Engl J Med. 2019 May 20. doi: 10.1056/NEJMoa1905248. [Epub ahead of print]

PMID:
31112385
4.

Lung Computational Models and the Role of the Small Airways in Asthma.

Foy BH, Soares M, Bordas R, Richardson M, Bell A, Singapuri A, Hargadon B, Brightling C, Burrowes K, Kay D, Owers-Bradley J, Siddiqui S.

Am J Respir Crit Care Med. 2019 May 18. doi: 10.1164/rccm.201812-2322OC. [Epub ahead of print]

PMID:
31106566
5.

Mepolizumab does not alter the blood basophil count in severe asthma.

Wright AKA, Diver S, McCarthy J, Marvin A, Soares M, Thornton T, Bourne M, Craner M, Evans H, Edwards S, Glover S, Carr L, Parker S, Siddiqui S, Cousins D, Brightling C.

Allergy. 2019 May 20. doi: 10.1111/all.13879. [Epub ahead of print] No abstract available.

PMID:
31106444
6.

T2 Biologics for Chronic Obstructive Pulmonary Disease.

Yousuf A, Ibrahim W, Greening NJ, Brightling CE.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1405-1416. doi: 10.1016/j.jaip.2019.01.036.

PMID:
31076058
7.

Airway inflammation in COPD- progress to precision medicine.

Brightling C, Greening N.

Eur Respir J. 2019 May 9. pii: 1900651. doi: 10.1183/13993003.00651-2019. [Epub ahead of print]

PMID:
31073084
8.

Cohort profile: Extended Cohort for E-health, Environment and DNA (EXCEED).

John C, Reeve NF, Free RC, Williams AT, Farmaki AE, Bethea J, Barton LM, Shrine N, Batini C, Packer R, Terry S, Hargadon B, Wang Q, Melbourne CA, Adams EL, Bee CE, Harrington K, Miola J, Brunskill NJ, Brightling CE, Barwell J, Wallace SE, Hsu R, Shepherd DJ, Hollox EJ, Wain LV, Tobin MD.

Int J Epidemiol. 2019 May 7. pii: dyz073. doi: 10.1093/ije/dyz073. [Epub ahead of print] No abstract available.

PMID:
31062032
9.

Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.

Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M; ATLANTIS study group.

Lancet Respir Med. 2019 May;7(5):402-416. doi: 10.1016/S2213-2600(19)30049-9. Epub 2019 Mar 12. Erratum in: Lancet Respir Med. 2019 Jul 15;:.

PMID:
30876830
10.

Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study.

Ibrahim W, Wilde M, Cordell R, Salman D, Ruszkiewicz D, Bryant L, Richardson M, Free RC, Zhao B, Yousuf A, White C, Russell R, Jones S, Patel B, Awal A, Phillips R, Fowkes G, McNally T, Foxon C, Bhatt H, Peltrini R, Singapuri A, Hargadon B, Suzuki T, Ng LL, Gaillard E, Beardsmore C, Ryanna K, Pandya H, Coates T, Monks PS, Greening N, Brightling CE, Thomas P, Siddiqui S.

BMJ Open. 2019 Mar 8;9(3):e025486. doi: 10.1136/bmjopen-2018-025486.

11.

DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment.

Saunders R, Kaul H, Berair R, Gonem S, Singapuri A, Sutcliffe AJ, Chachi L, Biddle MS, Kaur D, Bourne M, Pavord ID, Wardlaw AJ, Siddiqui SH, Kay RA, Brook BS, Smallwood RH, Brightling CE.

Sci Transl Med. 2019 Feb 13;11(479). pii: eaao6451. doi: 10.1126/scitranslmed.aao6451.

PMID:
30760581
12.

Breath analysis by two-dimensional gas chromatography with dual flame ionisation and mass spectrometric detection - Method optimisation and integration within a large-scale clinical study.

Wilde MJ, Cordell RL, Salman D, Zhao B, Ibrahim W, Bryant L, Ruszkiewicz D, Singapuri A, Free RC, Gaillard EA, Beardsmore C, Thomas CLP, Brightling CE, Siddiqui S, Monks PS.

J Chromatogr A. 2019 Jun 7;1594:160-172. doi: 10.1016/j.chroma.2019.02.001. Epub 2019 Feb 5.

13.

Functional CT imaging for identification of the spatial determinants of small-airways disease in adults with asthma.

Bell AJ, Foy BH, Richardson M, Singapuri A, Mirkes E, van den Berge M, Kay D, Brightling C, Gorban AN, Galbán CJ, Siddiqui S.

J Allergy Clin Immunol. 2019 Jul;144(1):83-93. doi: 10.1016/j.jaci.2019.01.014. Epub 2019 Jan 22.

PMID:
30682455
14.

Comparison of CT ventilation imaging and hyperpolarised gas MRI: effects of breathing manoeuvre.

Tahir BA, Marshall H, Hughes PJC, Brightling CE, Collier G, Ireland RH, Wild JM.

Phys Med Biol. 2019 Mar 7;64(5):055013. doi: 10.1088/1361-6560/ab0145.

PMID:
30673634
15.

Reply.

Farahi N, Loutsios C, Tregay N, Wright AKA, Berair R, Lok LSC, Gillett D, Cullum I, Simmonds RP, Summers C, Wong A, Solanki CK, Buscombe J, Pang PH, Thavakumar A, Peters AM, Brightling CE, Condliffe AM, Chilvers ER.

J Allergy Clin Immunol. 2019 Mar;143(3):1265-1266. doi: 10.1016/j.jaci.2018.11.026. Epub 2019 Jan 11. No abstract available.

PMID:
30639067
16.

Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study.

Shrine N, Portelli MA, John C, Soler Artigas M, Bennett N, Hall R, Lewis J, Henry AP, Billington CK, Ahmad A, Packer RJ, Shaw D, Pogson ZEK, Fogarty A, McKeever TM, Singapuri A, Heaney LG, Mansur AH, Chaudhuri R, Thomson NC, Holloway JW, Lockett GA, Howarth PH, Djukanovic R, Hankinson J, Niven R, Simpson A, Chung KF, Sterk PJ, Blakey JD, Adcock IM, Hu S, Guo Y, Obeidat M, Sin DD, van den Berge M, Nickle DC, Bossé Y, Tobin MD, Hall IP, Brightling CE, Wain LV, Sayers I.

Lancet Respir Med. 2019 Jan;7(1):20-34. doi: 10.1016/S2213-2600(18)30389-8. Epub 2018 Dec 11.

17.

Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST.

McKeever T, Mortimer K, Bradshaw L, Haydock R, Pavord I, Higgins B, Walker S, Wilson A, Price D, Thomas M, Devereux G, Brightling C, Renwick C, Parrott S, Mitchell E, Duley L, Harrison T.

Health Technol Assess. 2018 Dec;22(70):1-82. doi: 10.3310/hta22700.

18.

Sputum Moraxella catarrhalis strains exhibit diversity within and between COPD subjects.

George LM, Haigh RD, Mistry V, Haldar K, Barer MR, Oggioni MR, Brightling CE.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 8;13:3663-3667. doi: 10.2147/COPD.S180961. eCollection 2018.

19.

Exacerbations of severe asthma in patients treated with mepolizumab.

Shrimanker R, Pavord ID, Yancey S, Heaney LG, Green RH, Bradding P, Hargadon B, Brightling CE, Wardlaw AJ, Haldar P.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801127. doi: 10.1183/13993003.01127-2018. Print 2018 Dec. No abstract available.

PMID:
30464012
20.

Face mask sampling reveals antimicrobial resistance genes in exhaled aerosols from patients with chronic obstructive pulmonary disease and healthy volunteers.

Kennedy M, Ramsheh MY, Williams CML, Auty J, Haldar K, Abdulwhhab M, Brightling CE, Barer MR.

BMJ Open Respir Res. 2018 Sep 23;5(1):e000321. doi: 10.1136/bmjresp-2018-000321. eCollection 2018.

21.

ERS Clinical Research Collaborations: underpinning research excellence.

Brightling C, Genton C, Bill W, Welte T, Gaga M, Heuvelin E, Brusselle G.

Eur Respir J. 2018 Sep 15;52(3). pii: 1801534. doi: 10.1183/13993003.01534-2018. Print 2018 Sep. No abstract available.

PMID:
30219755
22.

In vivo imaging reveals increased eosinophil uptake in the lungs of obese asthmatic patients.

Farahi N, Loutsios C, Tregay N, Wright AKA, Berair R, Lok LSC, Gillett D, Cullum I, Simmonds RP, Summers C, Wong A, Solanki CK, Buscombe J, Pang PH, Thavakumar A, Peters AM, Brightling CE, Condliffe AM, Chilvers ER.

J Allergy Clin Immunol. 2018 Nov;142(5):1659-1662.e8. doi: 10.1016/j.jaci.2018.07.011. Epub 2018 Jul 30. No abstract available.

23.

Urgent need for pragmatic trial platforms in severe asthma.

Pilette C, Brightling C, Lacombe D, Brusselle G.

Lancet Respir Med. 2018 Aug;6(8):581-583. doi: 10.1016/S2213-2600(18)30291-1. No abstract available.

PMID:
30070256
24.

Modelling the effect of gravity on inert-gas washout outputs.

Foy BH, Gonem S, Brightling C, Siddiqui S, Kay D.

Physiol Rep. 2018 May;6(10):e13709. doi: 10.14814/phy2.13709.

25.

Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, Ulrik CS, Harrison T, Singh D, Chaudhuri R, Leaker B, McGarvey L, Siddiqui S, Wang M, Braddock M, Nordenmark LH, Cohen D, Parikh H, Colice G, Brightling CE; MESOS study investigators.

Lancet Respir Med. 2018 Jul;6(7):499-510. doi: 10.1016/S2213-2600(18)30201-7. Epub 2018 May 21.

PMID:
29793857
26.

Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.

Panettieri RA Jr, Sjöbring U, Péterffy A, Wessman P, Bowen K, Piper E, Colice G, Brightling CE.

Lancet Respir Med. 2018 Jul;6(7):511-525. doi: 10.1016/S2213-2600(18)30184-X. Epub 2018 May 20.

PMID:
29792288
27.

Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles.

Ghebre MA, Pang PH, Diver S, Desai D, Bafadhel M, Haldar K, Kebadze T, Cohen S, Newbold P, Rapley L, Woods J, Rugman P, Pavord ID, Johnston SL, Barer M, May RD, Brightling CE.

J Allergy Clin Immunol. 2018 Jun;141(6):2027-2036.e12. doi: 10.1016/j.jaci.2018.04.013. Epub 2018 Apr 28.

28.

In vitro, in silico and in vivo study challenges the impact of bronchial thermoplasty on acute airway smooth muscle mass loss.

Chernyavsky IL, Russell RJ, Saunders RM, Morris GE, Berair R, Singapuri A, Chachi L, Mansur AH, Howarth PH, Dennison P, Chaudhuri R, Bicknell S, Rose FRAJ, Siddiqui S, Brook BS, Brightling CE.

Eur Respir J. 2018 May 24;51(5). pii: 1701680. doi: 10.1183/13993003.01680-2017. Print 2018 May.

29.

Biologic Drugs: A New Target Therapy in COPD?

Yousuf A, Brightling CE.

COPD. 2018 Apr;15(2):99-107. doi: 10.1080/15412555.2018.1437897. Epub 2018 Apr 23. Review.

PMID:
29683730
30.

Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis.

Siddiqui S, Shikotra A, Richardson M, Doran E, Choy D, Bell A, Austin CD, Eastham-Anderson J, Hargadon B, Arron JR, Wardlaw A, Brightling CE, Heaney LG, Bradding P.

J Allergy Clin Immunol. 2018 Nov;142(5):1457-1468. doi: 10.1016/j.jaci.2017.12.982. Epub 2018 Mar 14.

PMID:
29550052
31.

Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists.

Bewley MA, Budd RC, Ryan E, Cole J, Collini P, Marshall J, Kolsum U, Beech G, Emes RD, Tcherniaeva I, Berbers GAM, Walmsley SR, Donaldson G, Wedzicha JA, Kilty I, Rumsey W, Sanchez Y, Brightling CE, Donnelly LE, Barnes PJ, Singh D, Whyte MKB, Dockrell DH; COPDMAP.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):739-750. doi: 10.1164/rccm.201705-0903OC.

32.

Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations.

McKeever T, Mortimer K, Wilson A, Walker S, Brightling C, Skeggs A, Pavord I, Price D, Duley L, Thomas M, Bradshaw L, Higgins B, Haydock R, Mitchell E, Devereux G, Harrison T.

N Engl J Med. 2018 Mar 8;378(10):902-910. doi: 10.1056/NEJMoa1714257. Epub 2018 Mar 3.

33.

Advancing the management of obstructive airways diseases through translational research.

Porsbjerg C, Sverrild A, Baines KJ, Searles A, Maltby S, Foster PS, Brightling C, Gibson PG.

Clin Exp Allergy. 2018 May;48(5):493-501. doi: 10.1111/cea.13112. Epub 2018 Mar 13. Review.

PMID:
29412485
34.

Fevipiprant in the treatment of asthma.

White C, Wright A, Brightling C.

Expert Opin Investig Drugs. 2018 Feb;27(2):199-207. doi: 10.1080/13543784.2018.1432592. Epub 2018 Jan 30. Review.

PMID:
29363343
35.

New and emerging drug treatments for severe asthma.

Diver S, Russell RJ, Brightling CE.

Clin Exp Allergy. 2018 Mar;48(3):241-252. doi: 10.1111/cea.13086. Epub 2018 Feb 13. Review.

PMID:
29315966
36.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.

Trials. 2018 Jan 4;19(1):5. doi: 10.1186/s13063-017-2384-7.

37.

Big asthma data: getting bigger and more beautiful?

Diver S, Brightling CE.

Thorax. 2018 Apr;73(4):311-312. doi: 10.1136/thoraxjnl-2017-211148. Epub 2017 Dec 29. No abstract available.

PMID:
29288213
38.

Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks.

Demenais F, Margaritte-Jeannin P, Barnes KC, Cookson WOC, Altmüller J, Ang W, Barr RG, Beaty TH, Becker AB, Beilby J, Bisgaard H, Bjornsdottir US, Bleecker E, Bønnelykke K, Boomsma DI, Bouzigon E, Brightling CE, Brossard M, Brusselle GG, Burchard E, Burkart KM, Bush A, Chan-Yeung M, Chung KF, Couto Alves A, Curtin JA, Custovic A, Daley D, de Jongste JC, Del-Rio-Navarro BE, Donohue KM, Duijts L, Eng C, Eriksson JG, Farrall M, Fedorova Y, Feenstra B, Ferreira MA; Australian Asthma Genetics Consortium (AAGC) collaborators, Freidin MB, Gajdos Z, Gauderman J, Gehring U, Geller F, Genuneit J, Gharib SA, Gilliland F, Granell R, Graves PE, Gudbjartsson DF, Haahtela T, Heckbert SR, Heederik D, Heinrich J, Heliövaara M, Henderson J, Himes BE, Hirose H, Hirschhorn JN, Hofman A, Holt P, Hottenga J, Hudson TJ, Hui J, Imboden M, Ivanov V, Jaddoe VWV, James A, Janson C, Jarvelin MR, Jarvis D, Jones G, Jonsdottir I, Jousilahti P, Kabesch M, Kähönen M, Kantor DB, Karunas AS, Khusnutdinova E, Koppelman GH, Kozyrskyj AL, Kreiner E, Kubo M, Kumar R, Kumar A, Kuokkanen M, Lahousse L, Laitinen T, Laprise C, Lathrop M, Lau S, Lee YA, Lehtimäki T, Letort S, Levin AM, Li G, Liang L, Loehr LR, London SJ, Loth DW, Manichaikul A, Marenholz I, Martinez FJ, Matheson MC, Mathias RA, Matsumoto K, Mbarek H, McArdle WL, Melbye M, Melén E, Meyers D, Michel S, Mohamdi H, Musk AW, Myers RA, Nieuwenhuis MAE, Noguchi E, O'Connor GT, Ogorodova LM, Palmer CD, Palotie A, Park JE, Pennell CE, Pershagen G, Polonikov A, Postma DS, Probst-Hensch N, Puzyrev VP, Raby BA, Raitakari OT, Ramasamy A, Rich SS, Robertson CF, Romieu I, Salam MT, Salomaa V, Schlünssen V, Scott R, Selivanova PA, Sigsgaard T, Simpson A, Siroux V, Smith LJ, Solodilova M, Standl M, Stefansson K, Strachan DP, Stricker BH, Takahashi A, Thompson PJ, Thorleifsson G, Thorsteinsdottir U, Tiesler CMT, Torgerson DG, Tsunoda T, Uitterlinden AG, van der Valk RJP, Vaysse A, Vedantam S, von Berg A, von Mutius E, Vonk JM, Waage J, Wareham NJ, Weiss ST, White WB, Wickman M, Widén E, Willemsen G, Williams LK, Wouters IM, Yang JJ, Zhao JH, Moffatt MF, Ober C, Nicolae DL.

Nat Genet. 2018 Jan;50(1):42-53. doi: 10.1038/s41588-017-0014-7. Epub 2017 Dec 22.

39.

Asthma.

Papi A, Brightling C, Pedersen SE, Reddel HK.

Lancet. 2018 Feb 24;391(10122):783-800. doi: 10.1016/S0140-6736(17)33311-1. Epub 2017 Dec 19. Review.

PMID:
29273246
40.

Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study.

Wang Z, Singh R, Miller BE, Tal-Singer R, Van Horn S, Tomsho L, Mackay A, Allinson JP, Webb AJ, Brookes AJ, George LM, Barker B, Kolsum U, Donnelly LE, Belchamber K, Barnes PJ, Singh D, Brightling CE, Donaldson GC, Wedzicha JA, Brown JR; COPDMAP.

Thorax. 2018 Apr;73(4):331-338. doi: 10.1136/thoraxjnl-2017-210741. Epub 2017 Dec 21.

41.

Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics.

Haldar K, Bafadhel M, Lau K, Berg A, Kwambana B, Kebadze T, Ramsheh MY, Barker B, Haldar P, Johnston S, Ketley JM, Brightling CE, Barer MR.

PLoS One. 2017 Aug 25;12(8):e0182833. doi: 10.1371/journal.pone.0182833. eCollection 2017.

42.

MUC5AC and a Glycosylated Variant of MUC5B Alter Mucin Composition in Children With Acute Asthma.

Welsh KG, Rousseau K, Fisher G, Bonser LR, Bradding P, Brightling CE, Thornton DJ, Gaillard EA.

Chest. 2017 Oct;152(4):771-779. doi: 10.1016/j.chest.2017.07.001. Epub 2017 Jul 14.

43.

Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome.

Engel M, Endesfelder D, Schloter-Hai B, Kublik S, Granitsiotis MS, Boschetto P, Stendardo M, Barta I, Dome B, Deleuze JF, Boland A, Müller-Quernheim J, Prasse A, Welte T, Hohlfeld J, Subramanian D, Parr D, Gut IG, Greulich T, Koczulla AR, Nowinski A, Gorecka D, Singh D, Gupta S, Brightling CE, Hoffmann H, Frankenberger M, Hofer TP, Burggraf D, Heiss-Neumann M, Ziegler-Heitbrock L, Schloter M, Zu Castell W.

PLoS One. 2017 Jul 13;12(7):e0180859. doi: 10.1371/journal.pone.0180859. eCollection 2017.

44.

Pathogenesis of asthma: implications for precision medicine.

Russell RJ, Brightling C.

Clin Sci (Lond). 2017 Jun 30;131(14):1723-1735. doi: 10.1042/CS20160253. Print 2017 Jul 15. Review.

PMID:
28667070
45.

American Thoracic Society/National Heart, Lung, and Blood Institute Asthma-Chronic Obstructive Pulmonary Disease Overlap Workshop Report.

Woodruff PG, van den Berge M, Boucher RC, Brightling C, Burchard EG, Christenson SA, Han MK, Holtzman MJ, Kraft M, Lynch DA, Martinez FD, Reddel HK, Sin DD, Washko GR, Wenzel SE, Punturieri A, Freemer MM, Wise RA.

Am J Respir Crit Care Med. 2017 Aug 1;196(3):375-381. doi: 10.1164/rccm.201705-0973WS.

46.

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.

Bilocca D, Hargadon B, Pavord ID, Green RH, Brightling CE, Bradding P, Wardlaw AJ, Martin N, Murphy AC, Siddiqui S.

Chron Respir Dis. 2018 Feb;15(1):85-87. doi: 10.1177/1479972317709650. Epub 2017 Jun 1.

47.

Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease Macrophages.

Bewley MA, Preston JA, Mohasin M, Marriott HM, Budd RC, Swales J, Collini P, Greaves DR, Craig RW, Brightling CE, Donnelly LE, Barnes PJ, Singh D, Shapiro SD, Whyte MKB, Dockrell DH.

Am J Respir Crit Care Med. 2017 Oct 1;196(7):845-855. doi: 10.1164/rccm.201608-1714OC.

48.

Human group 2 innate lymphoid cells do not express the IL-5 receptor.

Wright AKA, Weston C, Rana BMJ, Brightling CE, Cousins DJ.

J Allergy Clin Immunol. 2017 Nov;140(5):1430-1433.e4. doi: 10.1016/j.jaci.2017.04.025. Epub 2017 May 10. No abstract available.

49.

Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation.

Sousa AR, Marshall RP, Warnock LC, Bolton S, Hastie A, Symon F, Hargadon B, Marshall H, Richardson M, Brightling CE, Haldar P, Milone R, Chalk P, Williamson R, Panettieri R Jr, Knowles R, Bleecker ER, Wardlaw AJ.

Clin Exp Allergy. 2017 Jul;47(7):890-899. doi: 10.1111/cea.12954. Epub 2017 Jun 16.

PMID:
28493293
50.

Blood and sputum eosinophils in COPD; relationship with bacterial load.

Kolsum U, Donaldson GC, Singh R, Barker BL, Gupta V, George L, Webb AJ, Thurston S, Brookes AJ, McHugh TD, Wedzicha JA, Brightling CE, Singh D.

Respir Res. 2017 May 8;18(1):88. doi: 10.1186/s12931-017-0570-5.

Supplemental Content

Loading ...
Support Center